TL;DR — Citrus bergamot is a polyphenol-rich extract with placebo-controlled RCTs showing meaningful drops in LDL and triglycerides and a rise in HDL — a useful non-statin lever for lipids, and one that stacks additively on a statin. It works through the HMG-CoA pathway statins target, plus AMPK activation. Effect sizes vary by standardization and several trials come from one research group, so treat the larger numbers with mild caution. 500–1,000 mg/day standardized to flavonoids.
What citrus bergamot does (and why it matters)
Bergamot (Citrus bergamia) concentrates a distinctive set of flavonoids — brutieridin and melitidin — that behave like natural HMG-CoA reductase modulators. In human trials it lowers total and LDL cholesterol, drops triglycerides, and nudges HDL upward. For anyone building a metabolic or cardiovascular layer without — or alongside — a statin, that's a well-tolerated option with real trial support.
Primary hallmarks targeted: Deregulated nutrient sensing · Chronic inflammation · Altered intercellular communication
Mechanism — statin-like inhibition plus AMPKAn energy-sensing enzyme activated when ATP is low — it promotes fat burning, mitochondrial biogenesis, and autophagy. Full glossary →
| Pathway | Mechanism | Hallmark link |
|---|---|---|
| HMG-CoA reductase | Brutieridin/melitidin partially inhibit the rate-limiting step of cholesterol synthesis | Deregulated nutrient sensing |
| AMPK | Activation improves lipid handling and insulin sensitivity | Deregulated nutrient sensing |
| LDL oxidation | Antioxidant flavonoids lower oxidized-LDL, the atherogenic form | Chronic inflammation |
Evidence summary
| Study | Design | N | Duration | Key outcome | Tier |
|---|---|---|---|---|---|
| Mollace 2019 (PMID 30501605) | RCT (BPF / phytosome) | 60 | — | Lower fasting glucose, LDL, TG; higher HDL in T2DM + hyperlipidemia | B |
| Gliozzi 2013 (PMID 24239156) | RCT | 77 | 30 d | BPF 1000 mg lowered LDL-C and enhanced rosuvastatin's effect | B |
| Cicero 2021 (PMID 34345932) | Review / meta of lipid nutraceuticals | — | — | Places BPF among effective, well-tolerated lipid-lowering nutraceuticals | B |
← Swipe for more columns →
Consensus: Bergamot flavonoids lower LDL and triglycerides in mild-to-moderate dyslipidemia and add to a statin's effect. The reported magnitudes range widely (often 15–30%), and a meaningful share of the strongest trials come from a single Italian research group with industry ties — so the direction is solid, the exact effect size less so.
Where bergamot disappoints
- Familial / severe hypercholesterolemia — it is not a statin replacement where large LDL reductions are clinically required. - Headline effect sizes — independent replication tends to land below the biggest published numbers; standardization varies by brand. - Hard outcomes — no cardiovascular-event trials exist; the case rests on lipid surrogates.
What would change this grade. The tier is B because multiple RCTs agree on direction and it enhances statin therapy, but effect sizes are heterogeneous and partly industry-sourced. It would rise with large independent replication (and any outcome data), and fall if well-controlled independent trials shrank the lipid effect toward null.
Dosing protocol
| Parameter | Recommendation | Notes |
|---|---|---|
| Dose | 500–1,000 mg/day | Standardized to ~38% flavonoids |
| Timing | Before the largest meal | With food |
| Duration | 8–12 weeks before judging | Lipids move slowly |
Track your lipids
Log LDL, triglycerides, HDL and ideally ApoB at baseline and 12 weeks.
Open Labs hubMonitoring
Recheck a fasting lipid panel (LDL, triglycerides, HDL, and ideally ApoB) at baseline and 12 weeks. Add fasting glucose / HbA1c if you're using it for metabolic support.
Safety, red flags, and contraindications
- Well tolerated — mild GI upset is the most common complaint.
- Low furanocoumarin — unlike grapefruit, standardized bergamot extract is generally low in the furanocoumarins that drive CYP3A4 interactions.
Do not self-start without clearance
- Narrow-therapeutic-index drugs — confirm your product is furanocoumarin-reduced and clear it with a clinician.
- Already on a statin — the additive LDL drop is usually welcome, but coordinate dose changes.
Who should skip bergamot
- People who need guideline-level LDL lowering and should be on proven therapy. - Those on interacting medications without pharmacist review. - Anyone expecting a cardiovascular-outcome benefit — that evidence doesn't exist yet.
Synergies and antagonists
Pairs well with:
Works against / redundant with: No well-characterized antagonists at typical doses. Stacking multiple lipid nutraceuticals with overlapping mechanisms yields diminishing returns — measure, don't just add.
Personal results template
My bergamot results log
| Date | Week | Dose | LDL-C | Triglycerides | HDL | Notes |
|---|---|---|---|---|---|---|
| YYYY-MM-DD | 0 | — | — | — | — | Baseline |
| YYYY-MM-DD | 12 | — | — | — | — | Primary endpoint |
← Swipe for more columns →
Response criteria (personal, not clinical): - Meaningful: clear LDL or triglyceride reduction on a repeat fasting panel - Plateau: no lipid change by 12 weeks → reassess with your clinician - Adverse: persistent GI upset → reduce dose or stop
References
Links open PubMed. TNiC does not sell supplements; citations support education, not medical advice.